$CLVS
Clovis Oncology Inc
PRICE
$0.7285 ▲2.174%
Extented Hours
VOLUME
4,410,156
DAY RANGE
0.66 - 0.7375
52 WEEK
0.66 - 7.24
Join Discuss about CLVS with like-minded investors
@lucullus #droscrew
institutions loading up on bios during this sell off. Big pharma facing a patent cliff. $MYOV black rock tripled holding size, Bellevue doubled to close to 12%. Biotech 2nd half is going to be buyout land, MYOV, BCRX, AUPH, CLVS anything with a drug that produce revenues
62 Replies 11 👍 13 🔥
@singletary #StockTraders.NET
$mdvl I like it here as well. definitely cautious. I'm viewing it like $clvs
71 Replies 6 👍 13 🔥
@singletary #StockTraders.NET
$clvs down .50 so far will see what what it does in normal hours
68 Replies 7 👍 10 🔥
@singletary #StockTraders.NET
$clvs got the vwap covers. unfortunate on the rest. solid day. catch y'all tomorrow
103 Replies 15 👍 10 🔥
Key Metrics
Market Cap
102.63 M
Beta
1.71
Avg. Volume
7.44 M
Shares Outstanding
143.88 M
Yield
0%
Public Float
0
Next Earnings Date
2022-08-03
Next Dividend Date
Company Information
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado, with additional office locations in the U.S. and Europe.
CEO: Patrick Mahaffy
Website: www.clovisoncology.com
HQ: 5500 Flatiron Pkwy Unit 100 Boulder, 80301-2834 Colorado
Related News